I prefer to invest in biotechs where there is no significant risk that the mechanism-of-action doesn't work.
With this in mind, you might want to drill down some on NVIV. Their first product is neuro-scaffolding that apparently works quite well and is simply the first step and foundation for what might be a whole new paradigm in SCI treatment that might include insertion of stem cells and/or olfactory sheathing cells autologously harvested from the patients to increase the likelihood of new cell generation.
More on Olfactory ensheathing cells can be found in the following NYer article:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.